

1 Untargeted metabolomic study of autism in newborn screening samples: a pilot study.

2
3 Julie Courraud^{1,2}, Madeleine Ernst^{1,2}, Susan Svane Laursen¹, David M. Hougaard^{1,2}, Arie S. Cohen¹

4
5 ¹ Section for Clinical Mass Spectrometry, Department of Congenital Disorders, Danish Center for
6 Neonatal Screening, Statens Serum Institut Copenhagen, Copenhagen, Denmark

7 ² iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark

8
9 **Correspondence:** Julie Courraud (julc@ssi.dk), Section for Clinical Mass Spectrometry, Department
10 of Congenital Disorders, Danish Center for Neonatal Screening, Statens Serum Institut, Artillerivej 5,
11 2300 Copenhagen S, Denmark

12 ORCID 0000-0002-6797-7129

13 14 **Abstract:**

15 **Background**

16 The etiopathology of autism spectrum disorder (ASD) is unclear. Main risk factors include both genetic
17 and non-genetic factors, especially prenatal and perinatal events. The Danish Neonatal Screening
18 Biobank in connection with registry data provides unique opportunities to study early signs of disease.
19 Therefore, we aimed to study the metabolomic profiles of dried blood spot (DBS) of newborns later
20 diagnosed with ASD.

21 **Methods**

22 From the iPsych cohort, we randomly selected 37 subjects born in 2005 and diagnosed with ASD in
23 2012 (cases) together with 37 matched controls and submitted their biobanked DBS to an LC-MS/MS-
24 based untargeted metabolomics protocol. Raw data were preprocessed using MZmine 2.41.2 and

25 metabolites were subsequently putatively annotated using mzCloud, GNPS feature-based molecular
26 networking and other metabolome mining tools (MolNetEnhancer). Statistical analyses and data
27 visualization included principal coordinates analyses, PERMANOVAs, t-tests, and fold-change
28 analyses.

29 **Results**

30 4360 mass spectral features were detected, of which 150 could be putatively annotated at a high
31 confidence level. Chemical structure information at a broad level could be retrieved for a total of 1009
32 metabolites, covering 31 chemical classes including bile acids, various lipids, nucleotides, amino acids,
33 acylcarnitines and steroids. Although the untargeted analysis revealed no clear distinction between
34 cases and controls, 18 compounds repeatedly reported in the ASD literature could be detected in our
35 study and three mass spectral features were found differentially abundant in cases and controls before
36 FDR correction. In addition, our results pinpointed important other factors influencing chemical
37 profiles of newborn DBS samples such as gestational age, age at sampling and month of birth.

38 **Limitations**

39 Inherent to pilot studies, our sample size was insufficient to reveal metabolic markers of ASD.
40 Nevertheless, we were able to establish an efficient metabolomic data acquisition and analysis pipeline
41 and flag main confounders to be considered in future studies.

42 **Conclusions**

43 In this first untargeted DBS metabolomic study, newborns later diagnosed with ASD did not show a
44 significantly different metabolic profile when compared to controls. Nevertheless, our method covered
45 many metabolites associated with ASD in previous studies, suggesting that biochemical markers of
46 ASD are present at birth and may be monitored during newborn screening.

47

48 **Keywords:** autism, dried blood spots, untargeted metabolomics, newborn screening, biomarkers

49

50 **Background**

51 The etiopathology of ASD is still unclear and today ASD is diagnosed based on behavioral signs and
52 assessment of communication skills [1,2]. How the condition should be classified is debated [3,4], as
53 well as which tests offer the most reliable conclusions [1]. In Europe, detection services based on
54 behavioral signs are usually accessed on average at 18 months of age, and diagnosis occurs on average
55 at 36 months of age [5]. In this setting, early intervention is a challenge and has been reported to start in
56 Europe at 42 months of age on average [5]. Whether behavioral impairments are reflected in the blood
57 as biochemical abnormalities is still unsure, but the quest for biomarkers is legitimate, as they would
58 represent a useful tool to help in the diagnosis and treatment of ASD and in understanding its
59 underlying molecular mechanisms [6].

60

61 The main risk factors for ASD include genetic [7,8] and non-genetic factors, especially exposure during
62 fetal life [1,9–11]. Prenatal stress could influence fetal brain development and interact with genetic
63 predispositions thereby enhancing the risk of future psychiatric disorders [12,13]. Among prenatal
64 outcomes, maternal infection accompanied by fever during the second trimester of pregnancy has been
65 found to increase the risk of ASD twofold approximately [14]. Among perinatal outcomes, preterm
66 birth (<37 weeks) and low birthweight (small for gestational age) have been associated with an
67 increased risk of ASD as well as high frequency ventilation and intracranial hemorrhage [15]. Low
68 Apgar scores, a score used to summarize vital signs and assess health in newborns [16], also have
69 recently been associated with an increased risk of developing ASD [17].

70

71 Gastrointestinal tract disorders are often reported in ASD children, along with certain foods or diets
72 impacting the severity of symptoms [18–21]. There is a growing evidence of strong interactions

73 between gut and brain through microbiota [22,23], and these observations support the notion that ASD
74 is associated with metabolic malfunction such as decrease in sulphation capacity [18], and potentially
75 connected to gut microbial populations and functions [20]. It has also been shown that many small
76 molecules differing between normally-developing and ASD individuals likely result from microbial
77 metabolism [20,24,25]. Recently, plasma and stool metabolites have been associated with poor
78 communication scoring at age 3, and with good prediction of autism by age 8 [26]. Sharon and
79 collaborators (Sharon et al. 2019) have shown that microbiome and metabolome profiles of mice
80 harboring human microbiota predict that specific bacterial taxa and their metabolites modulate ASD
81 behaviors. They found that taurine and 5-amiovaleric acid (5AV) had significantly lower levels in ASD
82 mice and could show that when feeding BTBR mice either taurine or 5AV, autism-like symptoms such
83 as repetitive behavior and decreased social interaction could be decreased. In an intervention study,
84 treatment with *Lactobacillus reuteri* has been shown to have beneficial effects on ASD-related social
85 disturbances in mice [27]. In humans, intestinal microbiota transplantation has shown very promising
86 results, both against gastrointestinal tract symptoms and ASD symptoms, granting the therapy a ‘fast-
87 track’ status by the FDA [28]. Among the plasma metabolites showing average to good classification
88 capacity between the treated children and the controls, sarcosine, tyramine O-sulfate and inosine 5’-
89 monophosphate were selected as most discriminant [29]. Many of these studies postulate that
90 microbiota-derived molecules are transported across the blood-brain-barrier, acting as neuroactive
91 metabolites [22]. An impaired intestinal permeability or ‘leaky gut’ could also play a role in the effect
92 of microbiota activity on psychiatric disorders [30,31]. If gut microbial metabolites of potential impact
93 are indeed detectable in blood, this opens the door to blood-based investigations to further study and
94 understand the metabolomic differences between ASD and non-ASD individuals in the context of gut-
95 brain interactions.

96

97 Several studies have reported an altered metabolome associated with ASD during childhood, either in
98 blood [32–35,25,36–44], urine [18,38,45–56] or other matrices [25,57]. However, although some
99 biochemical biomarkers or set of biomarkers seem promising [6], none has yet been proven robust
100 enough for clinical practice. Furthermore, it remains unclear at what point in life biochemical
101 abnormalities of ASD are detectable.

102

103 To study the early role of genetic, prenatal and perinatal variables on disease development, samples
104 need to be collected shortly after birth. However, it is not practically and ethically straightforward to
105 draw blood from newborns prospectively. In many countries, the newborn screening programs are
106 conducted on dried blood spots (DBS) collected a few days after birth. In Denmark, such DBS are
107 stored in the Danish National Biobank and are available for research purposes for the last 30 years,
108 thereby covering approximately half of the country's population [58]. This allows researchers to
109 alleviate the biases inherent to recruitment in prospective clinical studies and instead retrospectively
110 retrieve the samples that are connected to the relevant metadata stored in centralized health registries.

111

112 Taking advantage of this unique resource, we here aimed at studying the strengths and limitations of
113 DBS samples in studying early biochemical abnormalities related to ASD development using an
114 untargeted metabolomics protocol. We compared the metabolomic profiles of newborns that have been
115 diagnosed with ASD at age 7 (cases) to newborns that have not (controls) and investigated potential
116 main confounders.

117

118 **Methods**

119 **Materials and methods**

120 *Materials*

121 Methanol (MeOH), acetonitrile (ACN), isopropanol (IPA), water (H₂O) and formic acid (FA) were of
122 Optima™ LCMS-grade and were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
123 Stable-isotope-labeled internal standards (IS) from the NeoBase Non-derivatized MSMS kit
124 (PerkinElmer, Waltham, MA, USA) were used. The exact list of compounds is provided in Additional
125 file 1.

126

127 *Subjects and samples*

128 Children (n=74) from the iPsych cohort [59] born in 2005 were randomly selected, of which 37 with a
129 diagnosis of autism spectrum disorder (ICD10 F84.0, F84.1, F84.5, F84.8 and/or F84.9) [2] at the date
130 of registry data extraction (2012), and 37 paired controls. Cases and controls were matched based on
131 gender and date of birth. Other metadata such as gestational age (GA), birthweight, age at sampling,
132 month of birth, mother's age at birth, and date of diagnosis, were also collected (when available).

133 Sample size was chosen for several reasons: 1) the unknown variation of metabolites in DBS made
134 power calculations impossible, hence why we needed a pilot study, 2) batch effect is a common
135 technical challenge in metabolomics, and analyzing all samples on one single 96-well plate was
136 expected to reduce technical variability, 3) DBS are highly precious samples.

137 DBS are full blood from newborns, aged between 48 and 72 hours, blotted onto Ahlstrom #226 filter
138 paper and left to dry for at least 3 hours at room temperature before being sent by mail at ambient
139 temperature to the Department of Congenital Disorders at the Statens Serum Institut in Copenhagen.

140 Subsequent to being used in the newborn screening program the samples are biobanked in the Danish
141 National Biobank (www.nationalbiobank.dk) at -20°C until they are retrieved for further research
142 analysis.

143

144 *Sample extraction*

145 A punch of 3.2-mm diameter was collected from each DBS using a Panthera-Puncher™ 9 blood spot
146 punching system (PerkinElmer) directly into a MicroPlate, non-coated 96-well clear polystyrene plate
147 (PerkinElmer). 100 µL of IS in extraction buffer were added to each well. The IS were labelled amino
148 acids (AA IS) and acylcarnitines (AC IS) diluted in 80% methanol (i.e. dilution factor of 1:330,
149 concentrations in Additional file 1). The plate was heat-sealed and shaken for 45 min at 750 rpm at
150 25°C in a PHMP-4 incubator. Then it was centrifuged for 30 min at 4000 rpm at 4 °C.

151 All the transferring steps were performed on a Microlab STAR line automated liquid handling
152 workstation using Venus software (Hamilton, Bonaduz, Switzerland).

153 The supernatant (75 µL) was transferred to a hard-shell 96-well polypropylene PCR plate (Bio-Rad)
154 and dried down with nitrogen 60 L/min at 25 °C for 1 hour on an EVX-192 (Apricot Designs
155 Evaporex). The residue was reconstituted in 75 µL 2.5% methanol, shaken for 15 min at 750 rpm at
156 25°C in a PHMP-4 incubator, and centrifuged 10 min at 4000 rpm at 4 °C. 65µL were transferred to a
157 hard-shell 96-well polypropylene PCR plate (Bio-Rad), heat-sealed, and centrifuged again for 5 min at
158 3000 rpm at 4 °C. The method from sample preparation to MS acquisition is also available as a table
159 according to the guidelines for standardization of LCMS method reporting [60] with adaptation to
160 metabolomics (Additional file 1).

161

162 *Quality assurance*

163 LC-MS/MS instrument performance was controlled by analyzing 4 pooled extracts, 8 solvent blanks,
164 and 3 paper blanks at regular intervals. Pooled extracts were made of 5 µL of reconstituted extract from
165 each of the samples (cases and controls only, total of 370 µL divided in four wells spread across the
166 plate) and were used to assess the consistency of extraction and data acquisition. Solvent blanks were
167 used to check for carry over and instrument noise, while paper blanks were used to monitor matrix
168 signals from the paper. Internal standards were used to control the quality of the extraction, elution, and

169 signal acquisition. Paired cases and controls were injected after one another but in a random order (first
170 case, then control, or vice-versa). Pairs were randomized over the plate.

171

172 *Liquid chromatography*

173 The samples were injected using an autosampler with stack cooler (Open Autosampler UltiMate OAS-
174 3300TXRS (Thermo Fisher Scientific)) and eluted through a Waters Acquity UPLC BEH C18 column
175 (130 Å, 2.1 mm x 50 mm, 1.7-µm particles) preceded by a Waters Acquity UPLC BEH C18 VanGuard
176 pre-column, 130 Å, 2.1 mm x 5 mm, 1.7-µm particles) using a Transcend II, LX-2 with UltiMate
177 pumps (Thermo Fisher Scientific). The pressure limits were set at 0.0 – 1034.0 bar.

178 The mobile phase consisted of solvent A (97.31% H₂O, 1.25% ACN, 1.25% MeOH and 0.2% FA), and
179 B (2.49% H₂O, 48.66% ACN, 48.66% MeOH and 0.2% FA).

180

181 The Wash1 solvent was mobile phase A and the Wash2 solvent mix was 25:25:25:25 v/v
182 MeOH:IPA:H₂O:ACN + 0.2% FA. The gradient (0.25 mL/min) started with 100% A : 0% B. After 0.5
183 min, we applied a gradient ramp to 0% A: 100% B over 8.5 minutes followed by a 0.5-min flow ramp
184 up to 0.9 mL/min and 5 minutes of 100% B. At 15 min, the column was equilibrated for 5.5 min with
185 100% A. At 17.5 min, the flow was changed back to 0.25 mL/min over 0.5 min. The total run time was
186 20.5 minutes, including 10 min sample run time and 10.5 min column wash and equilibration. The
187 column temperature was maintained at 60.0°C using a hot pocket column heater and the samples in the
188 autosampler were kept at 4°C throughout the analysis. The data was acquired in profile mode from 0.20
189 min and over 9.80 min.

190

191 *Mass spectrometry*

192 The Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) was operated with a heated
193 electrospray ionization source (HESI) in positive mode. The instruments were controlled using
194 TraceFinder 4.1 Clinical Research and Aria MX (Thermo Fisher Scientific). Mass range in MS full
195 scan mode was set to 70 to 1050 m/z with a resolution of 35,000. Automatic gain control was set to
196 1.10^6 , and maximum injection time at 100 ms. For data dependent-MS2 the resolution was set to
197 17,500. Automatic gain control was set to 1.10^5 , and maximum injection time at 50 ms. Loop count
198 was 5, isolation window 1.5 m/z and the stepped NCE 17.5, 35 and 52.5 eV. The spectrum data type
199 was set to Profile. In data dependent settings the Apex trigger was set to 2 to 7 s with 15s dynamic
200 exclusion and charge exclusion on 3-8 and >8. Diisooctylphthalate (391.28429 m/z) was selected as
201 lock mass. Other settings included the sheath gas pressure (N_2 , 32 psi), the auxiliary gas flow and
202 temperature (N_2 , 8 arb. units, 350°C), the S-lens radio frequency level (50.0%), the ion source
203 temperature (350°C), and the spray voltage (3.8 kV between 0-9.8 min and 1.0 kV between 9.8-10
204 min).

205

206 *LC-MS data preprocessing*

207 After conversion to .mzML (centroid) using MSConvertGUI v3.0 (ProteoWizard Software Foundation,
208 Palo Alto, CA, USA) [61], raw files were pre-processed using MZmine v2.41.2 [62,63]. All setting
209 details are provided in the batch .xml file (Additional file 2). Briefly, data were cropped based on
210 retention time (RT) 0.27-9.80 min. Masses were detected with a noise threshold of 10,000 for MS1 and
211 of 0 for MS2. The chromatogram was built using the ADAP module [64], with minimum 7 scans per
212 peak, a group intensity threshold of 10,000, a minimum highest intensity of 150,000, and a m/z
213 tolerance of 0.001 m/z or 5 ppm. Deconvolution was performed using the Wavelets (ADAP) module,
214 with m/z center calculation using median, and ranges for MS2 scan pairing of 0.01 Da and 0.4 min. The
215 isotopes were grouped with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min. Peaks

216 were aligned with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min, with 75% weight
217 given to m/z and 25% to RT. Finally, peaks were filtered with a minimum of fifteen peaks in a row, and
218 the same RT and peak duration ranges as previously applied. The feature quantification table (.csv) and
219 aggregated MS2 masses list (.mgf) were exported (no merging of MS/MS and filter rows: ALL) for
220 further analysis.

221

222 *Feature-based molecular networking using GNPS and compound annotation*

223 A molecular network was created with the feature-based molecular networking workflow ([https://ccms-](https://ccms-ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/)
224 [ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/](https://ccms-ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/)) [65] on the GNPS website
225 (<http://gnps.ucsd.edu>) [66] by uploading the aggregated MS2 mass list. The data was filtered by removing
226 all MS/MS fragment ions within +/- 17 Da of the precursor m/z . MS/MS spectra were window filtered
227 by choosing only the top 6 fragment ions in the +/- 50Da window throughout the spectrum. The precursor
228 ion mass tolerance was set to 0.02 Da and a MS/MS fragment ion tolerance of 0.02 Da. A network was
229 then created where edges were filtered to have a cosine score above 0.7 and more than 4 matched peaks.
230 Further, edges between two nodes were kept in the network if and only if each of the nodes appeared in
231 each other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family was
232 set to 100, and the lowest scoring edges were removed from molecular families until the molecular family
233 size was below this threshold. The spectra in the network were then searched against GNPS' spectral
234 libraries. The library spectra were filtered in the same manner as the input data. All matches kept between
235 network spectra and library spectra were required to have a score above 0.7 and at least 4 matched peaks.
236 The .graphml network file was then visualized using Cytoscape v3.7.2 [67] where individual sample data
237 and metadata were locally plotted (per sample and metadata sample group relative intensities). To
238 enhance annotation of potential compounds of interest using the mzCloud spectral library (Thermo Fisher
239 Scientific), .raw files were also preprocessed using Compound Discoverer 2.1 (CD2.1) SP1 software

240 (Thermo Fisher Scientific). Details regarding the settings are provided in Additional file 3. GNPS and
241 Compound Discoverer (annotation reported when above mzCloud 80% confidence in identity or
242 similarity search) offer annotations with a level 2 confidence according to the Metabolomics Standards
243 Initiative (i.e. putative annotation) [68,69]. To summarize and further enhance chemical structural
244 information within the molecular network, substructure information ([https://ccms-
245 ucsd.github.io/GNPSDocumentation/ms2lda/](https://ccms-ucsd.github.io/GNPSDocumentation/ms2lda/)) [70], information from *in silico* structure annotations from
246 Network Annotation Propagation [71] and Dereplicator [72] were incorporated using the GNPS
247 MolNetEnhancer workflow (<https://ccms-ucsd.github.io/GNPSDocumentation/molnetenhancer/>) [73]
248 with chemical class annotations retrieved from the ClassyFire chemical ontology [74]. When no chemical
249 structural information could be retrieved through the above searches, the MS/MS spectra were
250 additionally searched via MASST [75] and SIRIUS+CSI:FingerID [76–78]. MASST allows to query a
251 single MS/MS spectrum across all public GNPS datasets giving an idea of the type of samples or matrices
252 where the same MS/MS spectrum has been detected [75]. SIRIUS+CSI:FingerID uses deep learning
253 algorithms to predict the molecular and structural formula of a molecule from MS/MS spectra [76–79].

254

255 *Contamination filtering and further data curation*

256 Using a Kendrick Mass Filter, we explored the compositionality of our data to assess the potential
257 presence of undesired chemical background [80]. Out of the 4,360 features obtained through MZmine
258 preprocessing, more than 1,100 possessed repeat units typical of polyethylene glycol (PEG) and
259 polypropylene glycol (PPG). Filtering of PEG followed by filtering of PPG was performed using a
260 Kendrick Mass Filter [80] with the following parameters: number of observed signals = 5, Kendrick
261 mass defect = 0.01, and fraction base = 1 (see Additional file 4AB).

262 Of the 3,253 remaining features, we further excluded those with a maximum intensity in paper blanks /
263 maximum intensity in samples ratio ≥ 0.2 , as well as features with 20% or more gaps (i.e. missing
264 value) in cases and/or in controls (1,975 features filtered).

265

266 *Data visualization and outlier handling*

267 We performed principal coordinates analyses (PCoA) to visualize the data in an interactive 3D-space
268 using EMPEROR within QIIME 2 [81,82] using the Bray-Curtis, Canberra, Robust Aitchison [83] and
269 Jaccard distance metrics. This tool allowed us to easily map metadata on each sample in the 3D-space
270 and quickly detect broad patterns in the data, such as assessing the consistency of repeated pool
271 injections (i.e. repeated injections of the same pooled samples should cluster in PCoA space). When
272 performing these calculations on our “raw” unfiltered feature table (4,360 features), all tested distance
273 metrics showed seven samples as clear outliers, of which two controls and five cases. After
274 contamination filtering and data curation (1,281 features), six outliers remained since one outlier
275 (control) was due to PEG contamination. Among the investigated potential explanations for these
276 outliers, no pattern was found when looking at: position on the plate layout, potential RT shift
277 impairing the alignment, and metadata. However, targeted analysis of labeled internal standards and
278 unlabeled endogenous homologs showed that significant (but unexplained) errors occurred during
279 LCMS acquisition, with many undetectable compounds (TraceFinder 4.1 Clinical Research, Thermo
280 Fischer Scientific) (Additional file 5). A heatmap representation of the data (1,281 features) using
281 MetaboAnalyst 4.0 [84] confirmed the six outliers with very low intensities (Additional file 5).
282 Therefore, we decided to exclude these outliers from further statistical analyses and reran the PCoA
283 calculations on the remaining 68 samples.

284

285 *Statistics*

286 Using the calculated distance matrices from the PCoAs (1,281 features, 68 samples), we performed
287 Permutational Multivariate Analyses of Variance (PERMANOVAs) [85] to assess how much of the
288 variance in the data is explained by a certain variable in the metadata. We investigated the following
289 variables: autism (yes/no), autism subtype, gender, birthweight, gestational age, age at sampling, month
290 of birth, and injection order. The Adonis R^2 value indicates to what extent the variance is explained by
291 the tested variable. Significance threshold was set at 0.05. Calculations were performed using the *vegan*
292 and *ggplot2* packages in R software v3.6.1 [86].
293 Finally, the curated dataset (1,281 features, 68 samples, unpaired samples) was processed using
294 MetaboAnalyst 4.0 [84]. We excluded features with more than 50% missing values and replaced the
295 remaining missing values by a small value (half the minimum positive value in the original data). We
296 further filtered non-informative near-constant features based on interquartile range and applied a glog
297 transformation and Pareto scaling. We used a fold-change threshold of 2 (case/control or control/case)
298 and performed t-test and Wilcoxon rank-sum test with FDR correction for multiple comparisons. We
299 could not reliably use the Partial Least Squares Discriminant Analysis (negative Q2 in cross
300 validation). All Jupyter notebooks used for statistical analysis are publicly available on github
301 (https://github.com/madeleineernst/Autism_SupplementaryMaterial).

302

303 **Results**

304 *Subjects*

305 Subjects' characteristics are presented in Table 1 (details in Additional file 6). Cases and controls were
306 similar in terms of GA, birthweight, age at sampling and age of their mother at birth. The most
307 prevalent autism subtype was childhood autism. Most cases had only one diagnosis, but six had both
308 unspecified pervasive development disorder and autism (either childhood autism or atypical autism).

309 None had more than two diagnoses. Median age at first diagnosis was 5.6 years (range 1.1-7.8). Most
310 subjects were born at term (GA \geq 38 weeks). Only three cases and two controls were born preterm.

311

312 [Table 1]

313

314 *Molecular Network analysis*

315 From all features for which a MS2 spectrum has been acquired (2217 features over 4360) a feature-
316 based molecular network was computed via GNPS. Annotation could be retrieved for 150 features
317 (3.4%) of which 103 by matching to GNPS libraries (annotation level 2), and 47 by matching to our in-
318 house library using Trace Finder (annotation level 1, Additional file 7). Using the MolNetEnhancer
319 workflow [73], putative chemical structural information at the chemical class level, corresponding to a
320 level 3 annotation, could be retrieved for an additional 859 features. Hence, nearly 46% (1009) of the
321 mass spectral features could be putatively annotated at a level 1 to 3 (Additional file 7). Annotation
322 covered 31 chemical classes including 53 subclasses and 116 direct parents, such as medium-chain
323 fatty acids, phosphatidylcholines, nucleotides, amino acids, bile acids, steroids, acyl carnitines and
324 catecholamines.

325 Molecular families (independent clusters of nodes) from the 15 predominant putatively annotated
326 chemical classes are presented in Figure 1 (see details in Additional file 7). Plotting the average
327 intensities in the three groups (cases, controls, paper blanks) as well as fold change values (or p-values)
328 on the network nodes allowed for a quick overview of the molecular families with potential biological
329 relevance (See the example of bile acids in Figure 2). This analysis showed the potential of DBS in
330 covering various chemical classes and the power of feature-based molecular network analyses and
331 related metabolome mining tools in expanding the interpretability of complex untargeted metabolomics
332 data.

333

334 *Statistical analyses*

335 In PCoA space, repeated pool injections clustered satisfactorily showing that the LC-MS/MS data
336 acquisition was of acceptable quality (Figure 3). When looking at the two groups (cases/controls), no
337 clear separation was observed, even after removal of outliers (Figure 3A) and on all tested distance
338 metrics.

339 The PERMANOVAs (Figure 4, Additional file 8) revealed that the variance in the data was not
340 significantly explained by the grouping (cases/controls) (Bray-Curtis Adonis $R^2 = 0.014$, P-value =
341 0.777), even when distinguishing subtypes of ASD, although subtypes had a higher Adonis R^2 (Bray-
342 Curtis Adonis $R^2 = 0.070$, P-value = 0.707, see Table 1 for details on subtypes of ASD). Similarly, the
343 gender and birthweight did not significantly explain the variance in the data. However, variation in the
344 data explained by gestational age (Bray-Curtis Adonis $R^2 = 0.034$, P-value = 0.028), age at sampling
345 (Bray-Curtis Adonis $R^2 = 0.053$, P-value = 0.002) and especially month of birth (Bray-Curtis Adonis
346 $R^2 = 0.262$, P-value = 0.001, see Figure 3B) was significant, and to an increasing extent respectively
347 (greater Adonis R^2). On a technical level, we also observed a significant effect of injection order on the
348 data variation (Bray-Curtis Adonis $R^2 = 0.047$, P-value = 0.002), pointing to a limitation in our LC-
349 MS/MS method.

350

351 Results of univariate analyses and fold change analysis were carefully scrutinized feature by feature.
352 Considering our small sample size and potential pitfalls inherent to untargeted metabolomics related to
353 contaminants or integration errors, we thought essential to inspect each result to eliminate false
354 positives and spurious findings. Our inspection consisted of a five-step logic starting with peak
355 integration and shape quality (MZmine). We then plotted all individual intensity values to assess
356 whether the case/control difference was driven by four or fewer samples. If not, we reported the extent

357 of missing values in each group, checked the consistency of replicated pool injections, and finally
358 checked whether the feature was present in the feature-based molecular network, annotated as a
359 contaminant or in a node cluster with such annotation (Additional file 9). A large proportion of the
360 inspected features were excluded based on these criteria, showing the importance of such a verification
361 in order not to pursue spurious findings in future studies.

362 Among the 24 features with a fold change (case/control) value <0.5 or >2.0 , only one passed manual
363 inspection (Table 2, the full table is in Additional file 9). Eluting quite late (RT = 6.64 min, ID8605),
364 this relatively hydrophobic compound had a detected m/z of 1014.4892 and was not connected to any
365 other node in the network analysis (see its mass spectrum in Additional file 10). It could not be
366 annotated, but the algorithm of SIRIUS+CSI:FingerID pointed at a raw formula of $C_{36}H_{63}N_{21}O_{14}$
367 ($[M+H]^+$, only 7.12% scoring). This compound was more than twice as intense in controls as in cases
368 (FC 0.42, average intensity in cases $2.73E+05$ and controls $7.51E+05$), and would need further
369 investigation, especially as it was not detected in many samples (Additional file 9). A MASST search
370 was performed, however the feature with m/z 1014.4892 was not found in any of the public datasets on
371 GNPS.

372

373 [Table 2]

374

375 No feature was significantly differentially abundant in cases and controls according to the univariate
376 analyses with FDR correction for multiple comparisons (p values in Table 2).

377 Features that were differentially abundant before FDR correction are presented in Table 2. As a high
378 proportion of features were deemed irrelevant after inspection, we are presenting only the two relevant
379 features that passed our quality-control criteria. The full list and inspection details can be found in
380 Additional file 9. Methacholine was found to be significantly more abundant in cases when compared

381 to controls (average intensity in cases 4.41E+07 and controls 3.94E+07) both when using a t-test ($p =$
382 0.0021) and a Wilcoxon rank-sum test ($p = 0.0031$). The corresponding node (ID159) in the network
383 analysis was connected to another node with a mass difference of $-0.036 m/z$ (225 ppm) which could
384 not be annotated. None of the applied metabolome mining tools was able to retrieve chemical structural
385 information for the second compound significantly more abundant in cases than in controls (ID5593,
386 m/z 1014.4892, average intensity in cases 5.71E+05 and controls 4.35E+05). SIRIUS+CSI:Finger ID
387 predicted a molecular formula of $C_{11}H_{22}N_2O_3$ (M+H⁺, 99.96% scoring). Its RT of 2.78 min could
388 indicate a medium polarity with a logP between -1.0 and 0.5 when compared to tryptophan (RT 2.56
389 min, HMDB experimental logP -1.06) and hippuric acid (RT 3.04 min, HMDB experimental logP
390 0.31).

391 Among the 273 compounds reported in two recent reviews [6,87], 22 were cited at least three times, of
392 which 18 could be linked to features in our study after manual verification (Table 3, Additional file 11).

393

394 [Table 3]

395

396 **Discussion**

397 To assess the early signs of ASD development shortly after birth, we compared DBS samples from
398 newborns that have later on been diagnosed with ASD to newborns that have not. Our pilot study
399 showed the capacity of untargeted metabolomics as an analytical tool applied to biobanked DBS
400 samples to cover several metabolites relevant to ASD, thus suggesting that biochemical markers of
401 ASD are present at birth and could be targeted during neonatal screening. In addition, our method
402 pinpointed other factors which have a strong influence on the metabolic profile of newborn DBS, such

403 as gestational age, age at sampling and month of birth, and which are important to consider when
404 designing metabolomic studies in neonatal, biobanked DBS.

405 One study from 2013 was performed on newborn DBS samples from 16 autistic children and assessed
406 90 biomarkers (not only small molecules) using immunoassays [88] of which three sets of five were
407 associated with ASD. Another study was performed on DBS but in ASD children (n=83, age 2-10
408 years) and was targeting 45 metabolites [37], of which 9 were significantly higher in ASD children.
409 However, the potential of DBS in *untargeted* metabolomics studies has not yet been fully studied, and
410 never in the context of ASD (see recent reviews [6,87]).

411 Among the 22 compounds that had been repeatedly (≥ 3 times) reported in the literature to be involved
412 in ASD, 18 could be putatively annotated in our study, showing that our analytical pipeline covers
413 many relevant metabolites, including some specific to gut microbiota activity. Despite thorough
414 curation and inspection of the acquired data, no feature was significantly differentially abundant in
415 cases and controls after FDR correction. The small sample size as well as strong confounders could
416 play a role in the low power of this pilot study. Nonetheless, the PERMANOVA results showed that
417 subtypes of autism seemed to explain more variance in the data than just the case/control division
418 (higher Adonis R^2 , Figure 4). This could mean that subtypes have indeed distinct biochemical profiles
419 and should maybe be considered separately or in a stratified manner. Although, the lack of significance
420 could suggest that ASD genetic, prenatal and/or perinatal variables do not (sufficiently) translate into
421 biochemical abnormalities in newborns or that these are not detectable in biobanked DBS using our
422 current experimental setup, we were able to pinpoint 18 out of 22 metabolic markers associated with
423 ASD in previous studies. This finding suggests that rather the sample size and confounders are
424 responsible for the absent signal observed here, and future studies controlling for the here identified
425 confounders and greater sample size could provide more answers.

426

427 Among the hits and interesting findings of our pilot, we could show that a methacholine structural
428 analogue could be a relevant marker for ASD, as it was found at a higher although not significant
429 abundance in newborns that have been diagnosed with ASD at age 7. Methacholine is a choline ester
430 drug acting as non-selective muscarinic receptor agonist. It is mainly known as methacholine chloride
431 for its use in assessing bronchial hyper-reactivity in asthmatic patients. Although muscarinic receptors
432 were not associated with autism in children [89], lower estimates of ASD risk among children exposed
433 during fetal life to muscarinic receptor 2 agonists were reported [90]. Higher abundance of
434 methacholine in DBS of ASD cases, as seen in our study, would therefore not be easily explained and
435 demand further investigation. However, detecting a drug metabolite such as methacholine in newborn
436 samples is unexpected, thus it is more likely that this feature is an endogenous choline ester with
437 similar fragmentation behavior to methacholine.

438

439 Two other unknown features would benefit from being monitored in future studies. One relatively
440 hydrophobic compound (ID8605, m/z 1014.4892) showed an important fold change (much lower in
441 cases) but was not detected in many samples maybe due to low intensities. The second compound
442 (moderately polar, ID5593, m/z 1014.4892, $C_{11}H_{22}N_2O_3$) was significantly higher in cases before FDR
443 correction and detected in more than 65% of samples. Including both in an inclusion list for optimized
444 MS2 acquisition could provide higher quality spectra for better annotation. Overall, we observed poor
445 fragmentation of some analytes (4 fragmentation peaks or less) and optimization of fragmentation
446 parameters to a few targeted compounds, could enable better chemical structural annotation, although
447 fragmentation parameters such as other technical and sample preparation parameters, can never be
448 optimized for all compounds equally.

449

450 Although our study was not designed specifically to assess the tested confounders, we have shown that
451 gestational age, age at sampling and month of birth are strong drivers of metabolomic profiles in
452 newborns. This demonstrates the importance of considering these confounders when designing a future
453 study in newborn DBS.

454

455 Prematurity has been involved in numerous adverse health outcomes [91] and metabolic maturity has
456 been shown to be reflected in the blood and other matrices of infants after birth [92,93]. Although, in
457 the present study, only three cases and two controls were premature (<38 weeks of gestational age), we
458 saw a significant effect of gestational age on the metabolomic profile of newborns thus showing that
459 gestational age is an important factor to be controlled for in newborn DBS studies.

460

461 Similarly, we found that age at sampling has a significant impact on the newborn blood metabolome.
462 From 3 to 10 days of age, only one week has passed, and yet fundamental metabolic changes occur in
463 the newborn who is not anymore connected to his/her mother's blood, but exposed to various types of
464 nutrition and environmental conditions (healthcare, hospital vs home, etc.). The endogenous
465 anabolism/catabolism balance is in itself a strong variable to consider at that age. From 2009 onwards,
466 the Danish newborn screening program has indeed chosen to standardize the age at DBS sampling to
467 48 to 72 hours to optimize the window where potential inborn errors of metabolism would be detected
468 best and as early as possible since quick intervention is essential in such cases [94]. The iPsych cohort
469 was based on diagnoses of psychiatric disorders recorded in Danish health registry in 2012 [59]. Such
470 diagnoses are often given after several years of age, which is why the cohort did not cover subjects
471 born after 2005, year at which the age at sampling was not so narrowly standardized. The large sample
472 size of the iPsych cohort (almost 15,000 cases of ASD) should however allow for stricter selection
473 criteria in our future studies.

474

475 Another major change that occurs in newborns at birth and in the following days is the gut maturation
476 and its further colonization by microbes [95]. This topic has been under expanding attention in the last
477 decade, and the development and involvement of gut microbiota in neurodevelopment is being
478 scrutinized extensively [22]. The exact dynamics of the microbiota development in the placenta and
479 during the first days of life is still uncertain [95–97], as well as to what extent its activity can be
480 reflected in the blood. A recent study has shown that gut microbial alpha-diversity can be predicted
481 from the human blood metabolome [98] suggesting that microbial metabolites
482 explain a significant amount of the variance in the human blood metabolome. Thus, although sampled
483 at an early stage in life, it is plausible that microbial metabolites mediating health may be found in
484 dried blood spots from newborns [93]. Studying both fecal and blood samples will be essential to
485 answer questions related to the impact of gut microbes on the gut-brain axis, especially in the context
486 of psychiatric disorders where the brain is the main organ concerned but indeed located quite far from
487 the gut. Microbial metabolites would necessarily need to travel in the blood (or lymph) and through the
488 blood-brain barrier to interact with the brain. In our study, some detected metabolites could partly
489 derive from gut microbiota activity such as DL-Indole-3-lactic acid (ID3461, [99,100]), taurine (ID428,
490 level 3, [25]), various bile acids (Additional file 7, [57]), or inosine 5'-monophosphate (ID1133, level
491 3, [29]).

492

493 Lastly, we found that month of birth explains a significant variation in metabolomic profiles of
494 newborns (Figure 3b, Figure 4). Whether there is a yearly cyclic pattern or whether our findings are
495 specific to 2005 remains to be determined. Explanations could include aspects related to pregnancy
496 conditions varying along the year such as diet, weather conditions and sun exposure (e.g. impact on
497 vitamin D levels, type and extent of physical and social activities, mood and stress [101]), exposure to

498 “seasonal” infectious diseases (e.g. influenza), exposure to varying air quality (e.g. pollution or pollens
499 [102]), as well as storing conditions which might fluctuate over the year (e.g. sample transport at higher
500 temperatures during summer).

501

502 Gender and birthweight were not found to explain a significant part of the variance in the metabolomic
503 profiles of newborns in our study, despite the obvious connection between gestational age and
504 birthweight. The gender misbalance which reflects the gender disparity in ASD (a quarter were girls),
505 non-dedicated design, and small sample size could explain this finding. Some studies have indeed
506 reported that the profile of newborn girls and boys differed in, for instance, blood amino acids and
507 acylcarnitines [103], as well as urine profiles [104]. Despite our finding, we believe that gender and
508 birthweight should be adjusted for and taken into consideration when designing metabolomics studies
509 in newborns. Several of the tested confounders are inter-connected with, for instance, reports of more
510 males being born preterm [105] and females being born lighter [106], both associations being explained
511 by mechanisms that are likely to be reflected in the metabolome such as inflammatory response and
512 insulin resistance, respectively.

513

514 On the technical side, the strong effect of injection order is again a reminder that randomizing sample
515 pairs on the plates is fundamental in untargeted metabolomics. Although technical improvements can
516 be considered, it is extremely difficult if not impossible to avoid some level of signal drift and
517 carryover in untargeted metabolomics studies[107].

518

519 **Limitations and strengths**

520 To avoid batch effect and minimize the use of highly valuable and rare samples, we analyzed only 37
521 pairs of cases and controls in this pilot study. Despite the small sample size that did not confer enough

522 statistical power for pinpointing strong marker metabolites of ASD, we could detect numerous
523 metabolites associated with ASD in previous studies and identify a number of confounders to be
524 considered in future untargeted metabolomics study using newborn DBS. Other confounders not
525 evaluated in our study will need to be assessed in future studies, including metabolic changes in DBS
526 associated with time and storage conditions. Hematocrit variation could not be measured in our study
527 as we had access to only one punch of paper and did not have the possibility to measure a surrogate
528 marker such as potassium [108]. Furthermore, metabolites detected in this study are inherently
529 reflective of sampling protocols, including extraction protocols and MS acquisition parameters and
530 should be interpreted within these limitations.

531

532 **Conclusions**

533 This is the first study assessing metabolomic profiles of a psychiatric disorder, ASD in biobanked,
534 newborn DBS samples. The development of biobanks and reuse of systematically collected DBS
535 samples for research purposes in connection with registry data represent many new opportunities to
536 study the physiopathology and early signs of diseases, with extraordinary impacts in prevention,
537 diagnosis and treatment strategies. We showed that untargeted metabolomics on DBS samples offers a
538 wide and relevant coverage of metabolites for the study of ASD and that the new processing tools used
539 in our method largely expand the interpretability of such complex data.

540

541 **Declarations**

- 542 • Ethics approval and consent to participate

543 The Danish ethical committee approved the project (1-10-72-287-12). All blood samples can be stored
544 without explicit informed consent according to Danish law, and be reused for additional analysis

545 provided that projects are approved by the Research Ethics Committee and the Danish Data Protection
546 Agency. Although research projects require informed consent, the Research Ethics Committee can
547 waive this requirement if samples are anonymously processed, and if the projects do not imply any
548 health-related risk or burden to the subjects [109].

549

- 550 • Consent for publication

551 Not applicable

552

- 553 • Availability of data and materials

554 The datasets generated and/or analyzed during the current study are not publicly available due to the
555 risk of compromising individual privacy but are available from the corresponding author on reasonable
556 request and provided that an appropriate collaboration agreement can be agreed upon.

557

- 558 • Competing interests

559 The authors declare that they have no competing interests.

560

- 561 • Funding

562 This study was funded by The Lundbeck Foundation, Denmark.

563 This research has been conducted using the Danish National Biobank resource supported by the Novo
564 Nordisk Foundation grant number is 2010-11-12 and 2009-07-28.

565

566 *Disclaimer*

567 This funder had no involvement in any aspect of the study.

568

569 *Grant number*

570 R248-2017-2003 - Period III: 1 March 2018 - 28 February 2021

571 R155-2014-1724: Period II: 1 March 2015 – 28 February 2018

572 R102-A9118: Period I: 1 March 2012 – 28 February 2015

573

574 • Authors' contributions

575 JC and AC designed the study.

576 SSL collected the samples and ran the metabolomics analyses.

577 ME defined and coded major steps of data processing, chemical structural annotation and statistical
578 analysis and edited the manuscript.

579 JC processed the data, performed statistical analyses, and drafted the manuscript.

580 JC, ME, SSL and AC were involved in the manuscript edition and data interpretation, critically revised
581 the manuscript for important intellectual content, and approved the final version of this manuscript.

582 JC and AC had full access to all the data in the study and take responsibility for the integrity of the data
583 and the accuracy of the data analysis.

584

585 • Acknowledgements

586 We thank Anders Björkbom for his major contribution to the LCMS method development and Marie
587 Bækvad-Hansen for her help in curating data.

588

589 • Authors' information (optional)

590 Not applicable

591

592

593 **References**

594 1. Randall M, Egberts KJ, Samtani A, Scholten RJ, Hooft L, Livingstone N, et al. Diagnostic tests for autism
595 spectrum disorder (ASD) in preschool children. *Cochrane Database Syst Rev.* 2018;

596 2. World Health Organization. *The ICD-10 classification of mental and behavioural disorders: diagnostic criteria*
597 *for research.* Geneva: World Health Organization; 1993.

598 3. Adam D. Mental health: On the spectrum. *Nat News.* 2013;496:416.

599 4. Frances A. ICD, DSM and The Tower of Babel. *Aust N Z J Psychiatry.* 2014;48:371–3.

- 600 5. Bejarano-Martín Á, Canal-Bedia R, Magán-Maganto M, Fernández-Álvarez C, Cilleros-Martín MV, Sánchez-
601 Gómez MC, et al. Early Detection, Diagnosis and Intervention Services for Young Children with Autism
602 Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives. *J Autism Dev*
603 *Disord.* 2019;
- 604 6. Shen L, Liu X, Zhang H, Lin J, Feng C, Iqbal J. Biomarkers in autism spectrum disorders: Current progress.
605 *Clin Chim Acta Int J Clin Chem.* 2019;502:41–54.
- 606 7. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of Genetic and
607 Environmental Factors With Autism in a 5-Country Cohort. *JAMA Psychiatry.* 2019;76:1035–43.
- 608 8. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk
609 variants for autism spectrum disorder. *Nat Genet.* 2019;51:431–44.
- 610 9. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. The epidemiology of autism
611 spectrum disorders. *Annu Rev Public Health.* 2007;28:235–58.
- 612 10. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Andrews SV, et al. Elevated polygenic burden
613 for autism is associated with differential DNA methylation at birth. *Genome Med.* 2018;10.
- 614 11. Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low maternal melatonin level increases autism
615 spectrum disorder risk in children. *Res Dev Disabil.* 2018;82:79–89.
- 616 12. Abbott PW, Gumusoglu SB, Bittle J, Beversdorf DQ, Stevens HE. Prenatal stress and genetic risk: How
617 prenatal stress interacts with genetics to alter risk for psychiatric illness. *Psychoneuroendocrinology.* 2018;90:9–
618 21.
- 619 13. Fine R, Zhang J, Stevens HE. Prenatal stress and inhibitory neuron systems: implications for
620 neuropsychiatric disorders. *Mol Psychiatry.* 2014;19:641–51.
- 621 14. Croen LA, Qian Y, Ashwood P, Zerbo O, Schendel D, Pinto-Martin J, et al. Infection and Fever in
622 Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development. *Autism*
623 *Res.* 2019;12:1551–61.
- 624 15. Kuzniewicz MW, Wi S, Qian Y, Walsh EM, Armstrong MA, Croen LA. Prevalence and Neonatal Factors
625 Associated with Autism Spectrum Disorders in Preterm Infants. *J Pediatr.* 2014;164:20–5.
- 626 16. Apgar V. A proposal for a new method of evaluation of the newborn infant. *Curr Res Anesth Analg.*
627 1953;32:260–7.
- 628 17. Modabbernia A, Sandin S, Gross R, Leonard H, Gissler M, Parner ET, et al. Apgar score and risk of autism.
629 *Eur J Epidemiol.* 2019;34:105–14.
- 630 18. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic
631 children: a pilot study. *Biol Psychiatry.* 1999;46:420–4.
- 632 19. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental
633 delays or typical development. *J Autism Dev Disord.* 2014;44:1117–27.
- 634 20. Krajmalnik-Brown R, Lozupone C, Kang D-W, Adams JB. Gut bacteria in children with autism spectrum
635 disorders: challenges and promise of studying how a complex community influences a complex disease. *Microb*
636 *Ecol Health Dis.* 2015;26.

- 637 21. White JF. Intestinal pathophysiology in autism. *Exp Biol Med* Maywood NJ. 2003;228:639–49.
- 638 22. Cerdó T, Diéguez E, Campoy C. Early nutrition and gut microbiome: interrelationship between bacterial
639 metabolism, immune system, brain structure, and neurodevelopment. *Am J Physiol-Endocrinol Metab*.
640 2019;317:E617–30.
- 641 23. Wang S, Harvey L, Martin R, van der Beek EM, Knol J, Cryan JF, et al. Targeting the gut microbiota to
642 influence brain development and function in early life. *Neurosci Biobehav Rev*. 2018;95:191–201.
- 643 24. De Angelis M, Francavilla R, Piccolo M, De Giacomo A, Gobbetti M. Autism spectrum disorders and
644 intestinal microbiota. *Gut Microbes*. 2015;6:207–13.
- 645 25. Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, et al. Human Gut Microbiota from Autism
646 Spectrum Disorder Promote Behavioral Symptoms in Mice. *Cell*. 2019;177:1600-1618.e17.
- 647 26. Kelly RS, Boulin A, Laranjo N, Lee-Sarwar K, Chu SH, Yadama AP, et al. Metabolomics and
648 Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire.
649 *Metabolites*. 2019;9:42.
- 650 27. Sgritta M, Dooling SW, Buffington SA, Momin EN, Francis MB, Britton RA, et al. Mechanisms Underlying
651 Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder. *Neuron*.
652 2019;101:246-259.e6.
- 653 28. Adams JB, Borody TJ, Kang D-W, Khoruts A, Krajmalnik-Brown R, Sadowsky MJ. Microbiota transplant
654 therapy and autism: lessons for the clinic. *Expert Rev Gastroenterol Hepatol*. 2019;13:1033–7.
- 655 29. Adams JB, Vargason T, Kang D-W, Krajmalnik-Brown R, Hahn J. Multivariate Analysis of Plasma
656 Metabolites in Children with Autism Spectrum Disorder and Gastrointestinal Symptoms Before and After
657 Microbiota Transfer Therapy. *Processes*. 2019;7:806.
- 658 30. Borre YE, O’Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental
659 windows: implications for brain disorders. *Trends Mol Med*. 2014;20:509–18.
- 660 31. Magistris L de, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the Intestinal
661 Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives. *J Pediatr Gastroenterol*
662 *Nutr*. 2010;51:418–24.
- 663 32. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma Amino Acid Levels in Children with Autism and
664 Their Families. *J Autism Dev Disord*. 2003;33:93–7.
- 665 33. Evans C, Dunstan RH, Rothkirch T, Roberts TK, Reichelt KL, Cosford R, et al. Altered amino acid excretion
666 in children with autism. *Nutr Neurosci*. 2008;11:9–17.
- 667 34. De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazanetti DI, et al. Fecal Microbiota
668 and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified. *Plos*
669 *One*. 2013;8:e76993.
- 670 35. Kang D-W, Ilhan ZE, Isern NG, Hoyt DW, Howsmon DP, Shaffer M, et al. Differences in fecal microbial
671 metabolites and microbiota of children with autism spectrum disorders. *Anaerobe*. 2018;49:121–31.
- 672 36. Naushad SM, Jain JMN, Prasad CK, Naik U, Akella RRD. Autistic children exhibit distinct plasma amino
673 acid profile. *Indian J Biochem Biophys*. 2013;50:474–8.

- 674 37. Barone R, Alaimo S, Messina M, Pulvirenti A, Bastin J, Group M-A, et al. A Subset of Patients With Autism
675 Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses. *Front Psychiatry*.
676 2018;9.
- 677 38. Anwar A, Abruzzo PM, Pasha S, Rajpoot K, Bolotta A, Ghezzi A, et al. Advanced glycation endproducts,
678 dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. *Mol*
679 *Autism*. 2018;9:3.
- 680 39. Smith AM, King JJ, West PR, Ludwig MA, Donley ELR, Burrier RE, et al. Amino Acid Dysregulation
681 Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism
682 Spectrum Disorder. *Biol Psychiatry*. 2019;85:345–54.
- 683 40. West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, et al. Metabolomics as a Tool for
684 Discovery of Biomarkers of Autism Spectrum Disorder in the Blood Plasma of Children. *PLoS ONE*. 2014;9.
- 685 41. Rangel-Huerta OD, Gomez-Fernández A, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K,
686 et al. Metabolic profiling in children with autism spectrum disorder with and without mental regression:
687 preliminary results from a cross-sectional case-control study. *Metabolomics Off J Metabolomic Soc*. 2019;15:99.
- 688 42. Bitar T, Mavel S, Emond P, Nadal-Desbarats L, Lefèvre A, Mattar H, et al. Identification of metabolic
689 pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. *J*
690 *Pharm Biomed Anal*. 2018;152:57–65.
- 691 43. Delaye J-B, Patin F, Lagrue E, Le Tilly O, Bruno C, Vuillaume M-L, et al. Post hoc analysis of plasma
692 amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. *Ann Clin*
693 *Biochem*. SAGE Publications; 2018;55:543–52.
- 694 44. Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M, et al. Altered Metabolites in the
695 Plasma of Autism Spectrum Disorder: A Capillary Electrophoresis Time-of-Flight Mass Spectroscopy Study.
696 *PLoS ONE*. 2013;8.
- 697 45. Retey J. The Urocanase Story: A Novel Role of NAD⁺ as Electrophile. *Arch Biochem Biophys*. 1994;314:1–
698 16.
- 699 46. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPPA), an
700 abnormal phenylalanine metabolite of *Clostridia* spp. in the gastrointestinal tract, in urine samples from patients
701 with autism and schizophrenia. *Nutr Neurosci*. 2010;13:135–43.
- 702 47. Mavel S, Nadal-Desbarats L, Blasco H, Bonnet-Brilhault F, Barthélémy C, Montigny F, et al. 1H-13C NMR-
703 based urine metabolic profiling in autism spectrum disorders. *Talanta*. 2013;114:95–102.
- 704 48. Yap IKS, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping
705 differentiates children with autism from their unaffected siblings and age-matched controls. *J Proteome Res*.
706 2010;9:2996–3004.
- 707 49. Ming X, Stein TP, Barnes V, Rhodes N, Guo L. Metabolic perturbation in autism spectrum disorders: a
708 metabolomics study. *J Proteome Res*. 2012;11:5856–62.
- 709 50. Liu A, Zhou W, Qu L, He F, Wang H, Wang Y, et al. Altered Urinary Amino Acids in Children With Autism
710 Spectrum Disorders. *Front Cell Neurosci*. 2019;13.

- 711 51. Kałużna-Czaplińska J. Noninvasive urinary organic acids test to assess biochemical and nutritional
712 individuality in autistic children. *Clin Biochem.* 2011;44:686–91.
- 713 52. Lussu M, Noto A, Masili A, Rinaldi AC, Dessì A, Angelis MD, et al. The urinary ¹H-NMR metabolomics
714 profile of an Italian autistic children population and their unaffected siblings. *Autism Res.* 2017;10:1058–66.
- 715 53. Chen Q, Qiao Y, Xu X, You X, Tao Y. Urine Organic Acids as Potential Biomarkers for Autism-Spectrum
716 Disorder in Chinese Children. *Front Cell Neurosci.* 2019;13.
- 717 54. Emond P, Mavel S, Aïdoud N, Nadal-Desbarats L, Montigny F, Bonnet-Brilhault F, et al. GC-MS-based
718 urine metabolic profiling of autism spectrum disorders. *Anal Bioanal Chem.* 2013;405:5291–300.
- 719 55. Noto A, Fanos V, Barberini L, Grapov D, Fattuoni C, Zaffanello M, et al. The urinary metabolomics profile
720 of an Italian autistic children population and their unaffected siblings. *J Matern Fetal Neonatal Med.*
721 2014;27:46–52.
- 722 56. Gevi F, Zolla L, Gabriele S, Persico AM. Urinary metabolomics of young Italian autistic children supports
723 abnormal tryptophan and purine metabolism. *Mol Autism.* 2016;7:47.
- 724 57. Wang M, Wan J, Rong H, He F, Wang H, Zhou J, et al. Alterations in Gut Glutamate Metabolism Associated
725 with Changes in Gut Microbiota Composition in Children with Autism Spectrum Disorder. *mSystems. American*
726 *Society for Microbiology Journals;* 2019;4.
- 727 58. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening Biobank. *J*
728 *Inherit Metab Dis.* 2007;30:530–6.
- 729 59. Pedersen CB, Bybjerg-Grauholm J, Pedersen MG, Grove J, Agerbo E, Bækvad-Hansen M, et al. The
730 iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of
731 severe mental disorders. *Mol Psychiatry.* 2018;23:6–14.
- 732 60. Vogeser M, Schuster C, Rockwood AL. A proposal to standardize the description of LC-MS-based
733 measurement methods in laboratory medicine. *Clin Mass Spectrom.* 2019;13:36–8.
- 734 61. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, et al. A cross-platform toolkit
735 for mass spectrometry and proteomics. *Nat Biotechnol.* 2012;30:918–20.
- 736 62. Katajamaa M, Miettinen J, Oresic M. MZmine: toolbox for processing and visualization of mass
737 spectrometry based molecular profile data. *Bioinforma Oxf Engl.* 2006;22:634–6.
- 738 63. Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2: Modular framework for processing,
739 visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC Bioinformatics.* 2010;11:395.
- 740 64. Myers OD, Sumner SJ, Li S, Barnes S, Du X. One Step Forward for Reducing False Positive and False
741 Negative Compound Identifications from Mass Spectrometry Metabolomics Data: New Algorithms for
742 Constructing Extracted Ion Chromatograms and Detecting Chromatographic Peaks. *Anal Chem.* 2017;89:8696–
743 703.
- 744 65. Nothias LF, Petras D, Schmid R, Dührkop K, Rainer J, Sarvepalli A, et al. Feature-based Molecular
745 Networking in the GNPS Analysis Environment. *bioRxiv.* 2019;812404.

- 746 66. Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of
747 mass spectrometry data with Global Natural Products Social Molecular Networking. *Nat Biotechnol.*
748 2016;34:828–37.
- 749 67. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment
750 for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13:2498–504.
- 751 68. Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics Strategies—
752 Challenges and Emerging Directions. *J Am Soc Mass Spectrom.* 2016;27:1897–905.
- 753 69. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting
754 standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative
755 (MSI). *Metabolomics.* 2007;3:211–21.
- 756 70. Hooft JJJ van der, Wandy J, Barrett MP, Burgess KEV, Rogers S. Topic modeling for untargeted
757 substructure exploration in metabolomics. *Proc Natl Acad Sci.* 2016;113:13738–43.
- 758 71. Silva RR da, Wang M, Nothias L-F, Hooft JJJ van der, Caraballo-Rodríguez AM, Fox E, et al. Propagating
759 annotations of molecular networks using in silico fragmentation. *PLOS Comput Biol.* 2018;14:e1006089.
- 760 72. Mohimani H, Gurevich A, Mikheenko A, Garg N, Nothias L-F, Ninomiya A, et al. Dereplication of peptidic
761 natural products through database search of mass spectra. *Nat Chem Biol.* 2017;13:30–7.
- 762 73. Ernst M, Kang KB, Caraballo-Rodríguez AM, Nothias L-F, Wandy J, Chen C, et al. MolNetEnhancer:
763 Enhanced Molecular Networks by Integrating Metabolome Mining and Annotation Tools. *Metabolites.*
764 2019;9:144.
- 765 74. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, et al. ClassyFire: automated
766 chemical classification with a comprehensive, computable taxonomy. *J Cheminformatics.* 2016;8:61.
- 767 75. Wang M, Jarmusch AK, Vargas F, Aksenov AA, Gauglitz JM, Weldon K, et al. Mass spectrometry searches
768 using MASST. *Nat Biotechnol.* 2020;38:23–6.
- 769 76. Böcker S, Dührkop K. Fragmentation trees reloaded. *J Cheminformatics.* 2016;8:5.
- 770 77. Dührkop K, Shen H, Meusel M, Rousu J, Böcker S. Searching molecular structure databases with tandem
771 mass spectra using CSI:FingerID. *Proc Natl Acad Sci U S A.* 2015;112:12580–5.
- 772 78. Dührkop K, Fleischauer M, Ludwig M, Aksenov AA, Melnik AV, Meusel M, et al. SIRIUS 4: a rapid tool
773 for turning tandem mass spectra into metabolite structure information. *Nat Methods.* 2019;16:299–302.
- 774 79. Shen H, Dührkop K, Böcker S, Rousu J. Metabolite identification through multiple kernel learning on
775 fragmentation trees. *Bioinforma Oxf Engl.* 2014;30:i157-164.
- 776 80. da Silva RR, Vargas F, Ernst M, Nguyen NH, Bolleddu S, del Rosario KK, et al. Computational Removal of
777 Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter. *J Am Soc Mass*
778 *Spectrom.* 2019;30:268–77.
- 779 81. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive,
780 scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol.* 2019;37:852–7.

- 781 82. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeRor: a tool for visualizing high-throughput
782 microbial community data. *GigaScience*. 2013;2.
- 783 83. Martino C, Morton JT, Marotz CA, Thompson LR, Tripathi A, Knight R, et al. A Novel Sparse
784 Compositional Technique Reveals Microbial Perturbations. *mSystems*. 2019;4:e00016-19.
- 785 84. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and
786 integrative metabolomics analysis. *Nucleic Acids Res*. 2018;46:W486–94.
- 787 85. Anderson MJ. A new method for non-parametric multivariate analysis of variance. *Austral Ecol*.
788 2001;26:32–46.
- 789 86. R Core Team. R: a language and environment for statistical computing [Internet]. R Found. Stat. Comput.
790 Vienna Austria. 2019 [cited 2019 Nov 21]. Available from: <https://www.R-project.org/>
- 791 87. Glinton KE, Elsea SH. Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future
792 Directions. *Front Psychiatry*. 2019;10.
- 793 88. Mizejewski GJ, Lindau-Shepard B, Pass KA. Newborn screening for autism: in search of candidate
794 biomarkers. *Biomark Med*. 2013;7:247–60.
- 795 89. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the
796 cerebellar cortex in autism. *Brain J Neurol*. 2002;125:1483–95.
- 797 90. Janecka M, Kodesh A, Levine SZ, Lusskin SI, Viktorin A, Rahman R, et al. Association of Autism Spectrum
798 Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. *JAMA Psychiatry*.
799 2018;75:1217–24.
- 800 91. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *The*
801 *Lancet*. 2008;371:261–9.
- 802 92. Gil AM, Duarte D. Biofluid Metabolomics in Preterm Birth Research. *Reprod Sci*. 2018;25:967–77.
- 803 93. Ernst M, Rogers S, Lausten-Thomsen U, Bjorkbom A, Laursen SS, Courraud J, et al. Gestational-age-
804 dependent development of the neonatal metabolome. *medRxiv*. Cold Spring Harbor Laboratory Press;
805 2020;2020.03.27.20045534.
- 806 94. Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B. “Classical” organic acidurias, propionic
807 aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn
808 screening using tandem mass spectrometry. *J Inherit Metab Dis*. Springer; 2006;29:383–9.
- 809 95. Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The First Microbial Colonizers of the
810 Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. *Microbiol Mol Biol*
811 *Rev MMBR*. 2017;81.
- 812 96. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and Stabilization of
813 the Human Gut Microbiome during the First Year of Life. *Cell Host Microbe*. 2015;17:690–703.
- 814 97. Rosa PSL, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore CM, et al. Patterned progression
815 of bacterial populations in the premature infant gut. *Proc Natl Acad Sci*. 2014;111:12522–7.

- 816 98. Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, et al. Blood metabolome predicts gut
817 microbiome α -diversity in humans. *Nat Biotechnol.* 2019;37:1217–28.
- 818 99. Meng D, Sommella E, Salviati E, Campiglia P, Ganguli K, Djebali K, et al. Indole-3-lactic acid, a metabolite
819 of tryptophan, secreted by *Bifidobacterium longum* subspecies *infantis* is anti-inflammatory in the immature
820 intestine. *Pediatr Res.* Nature Publishing Group; 2020;1–9.
- 821 100. Laursen MF, Sakanaka M, Burg N von, Andersen D, Mörbe U, Rivollier A, et al. Breastmilk-promoted
822 bifidobacteria produce aromatic lactic acids in the infant gut. *bioRxiv.* Cold Spring Harbor Laboratory;
823 2020;2020.01.22.914994.
- 824 101. Keller MC, Fredrickson BL, Ybarra O, Cote S, Johnson K, Mikels J, et al. A warm heart and a clear head -
825 The contingent effects of weather on mood and cognition. *Psychol Sci.* Blackwell Publishing; 2005;16:724–31.
- 826 102. D’Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M, et al. Meteorological
827 conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the
828 World Allergy Organization. *World Allergy Organ J.* Elsevier; 2015;8:UNSP 25.
- 829 103. Ruoppolo M, Scolamiero E, Caterino M, Mirisola V, Franconi F, Campesi I. Female and male human
830 babies have distinct blood metabolomic patterns. *Mol Biosyst.* 2015;11:2483–92.
- 831 104. Diaz SO, Pinto J, Barros AS, Morais E, Duarte D, Negrão F, et al. Newborn Urinary Metabolic Signatures
832 of Prematurity and Other Disorders: A Case Control Study. *J Proteome Res.* 2016;15:311–25.
- 833 105. Challis J, Newnham J, Petraglia F, Yeganegi M, Bocking A. Fetal sex and preterm birth. *Placenta.*
834 2013;34:95–9.
- 835 106. Wilkin TJ, Murphy MJ. The gender insulin hypothesis: why girls are born lighter than boys, and the
836 implications for insulin resistance. *Int J Obes.* 2006;30:1056–61.
- 837 107. Wehrens R, Hageman JosA, van Eeuwijk F, Kooke R, Flood PJ, Wijnker E, et al. Improved batch
838 correction in untargeted MS-based metabolomics. *Metabolomics.* 2016;12.
- 839 108. Petrick L, Edmands W, Schiffman C, Grigoryan H, Perttula K, Yano Y, et al. An untargeted metabolomics
840 method for archived newborn dried blood spots in epidemiologic studies. *Metabolomics Off J Metabolomic Soc.*
841 2017;13.
- 842 109. Folketinget. Bekendtgørelse af lov om videnskabetisk behandling af sundhedsvidenskabelige
843 forskningsprojekter - (The Danish Parliament. Order of law on scientific treatment of health scientific research
844 projects) [Internet]. *retsinformation.dk.* 2017 [cited 2019 Oct 28]. Available from:
845 <https://www.retsinformation.dk/Forms/r0710.aspx?id=192671>

846

847 **Tables**

848 **Table 1. Subjects characteristics**

	All subjects n = 74				After outlier removal n = 68				
	cases		controls		cases		controls		
Age at 1st Jan. 2006 (months, median (range))	7.6	(0.8-11.6)	7.6	(0.8-11.6)	7.3	(0.8-11.6)	7.5	(0.8-11.6)	
Gender (girls / boys)	8 / 29		8 / 29		7 / 25		8 / 28		
Classification of cases (ICD10)¹									
- F84.0 Childhood autism	17		-		15		-		
- F84.1 Atypical autism	7		-		6		-		
- F84.5 Asperger syndrome	4		-		3		-		
- F84.8 Other pervasive developmental disorders	4		-		4		-		
- F84.9 Unspecified pervasive developmental disorders	11		-		10		-		
Gestational age (weeks, median (range), NA)	40	(33-42)	5	39 (30-42)	2	40 (33-41)	4	39 (30-42)	2
Birthweight (g, median (range), NA)	3500	(2210-4880)	1	3480 (977-4850)	2	3498 (2210-4880)	0	3490 (977-4850)	2
Age at sampling (days, median (range), NA)	6	(3-9)	3	6 (4-10)	3	6 (3-9)	2	6 (4-10)	3
Age of mother at birth (years, median (range))	31.7	(20.8-41.5)	31.7	(18.3-41.2)	32.3	(20.8-41.5)	31.8	(18.3-41.2)	

849 ¹ ICD10 classification [2]

850 More details are provided in Additional file 6.

851

852

853

854 **Table 2. Differentially abundant features in univariate analyses without FDR correction (p<0.01) and/or with high fold-change**
 855 **meeting inspection criteria**

Putative annotation of relevant compounds	Annotation level ¹	m/z	RT (min)	ID	p-value t-test		p-value Wilcoxon rank-sum test		FC ²	Network connections ³
					without FDR correction	with FDR correction	without FDR correction	with FDR correction		
Methacholine C ₈ H ₁₈ NO ₂ ⁺	2 ⁴	160.13315	0.45	159	0.0021	0.9174	0.0031	0.9434	1.25	connected to 1853 (-0.036 m/z)
SIRIUS 99.96%: C ₁₁ H ₂₂ N ₂ O ₃ (M+H ⁺)	4	231.17005	2.78	5593	0.0072	0.9174	0.0138	0.9434	1.46	Single node
SIRIUS 7.12%: C ₃₆ H ₆₃ N ₂₁ O ₁₄ (M+H ⁺)	4	1014.48923	6.64	8605	0.0414	0.9174	0.0179	0.9434	0.42	Single node

856 ¹ Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].

857 ² FC: Fold-change (case/control)

858 ³ Network connections in GNPS feature-based molecular network.

859 ⁴ Source of annotation mzCloud (89.9% score). See its mass spectrum in Additional file 10.

860 Inspection criteria: peak integration or shape quality, initial missing values, single values plot, presence and consistence in replicated
 861 pool injections, annotation or connection to contaminants. For details see Additional file 7.

862

863

864

865

866

867

868 **Table 3. Compounds reported in the literature three or more times as being associated with ASD**

Compound name	Annotation level ¹	Raw formula	<i>m/z</i> [M+H] ⁺	RT (min)	Feature ID (MZmine 2.41)	Detected by Compound Discoverer 2.1	HMDB ID	Literature reference
Arginine	1	C6H14N4O2	175.11895	0.35	1450	ND	HMDB0000517	[38,44,50]
Aspartic acid	1	C4H7NO4	134.04478	0.41	1073	ND	HMDB0000191	[34,35,40,41,50,57]
Citric acid	4	C6H8O7	193.03428	0.35	1776	yes	HMDB0000094	[40,42,51]
Creatine	2	C4H9N3O2	132.07675	0.40	16	yes	HMDB0000064	[42,47,52]
Creatinine	2	C4H7N3O	114.06619	0.40	281	yes	HMDB0000562	[40,50,52,53]
Decanoylcarnitine	1	C17H33NO4	316.24823	6.00	3633	yes	HMDB0000651	[37,41,57]
Glutamic acid	1	C5H9NO4	148.06043	0.38	136	yes	HMDB0000148	[34,35,38,40–43,52]
Glutamine	2	C5H10N2O3	147.07642	0.40	107	yes	HMDB0000641	[35,38,39]
Glycine	3	C2H5NO2	76.03930	0.38	1177	ND	HMDB0000123	[34,39,43,47,49,52]
Glycolic acid	-	C2H4O3	77.02332	-	ND	ND	HMDB0000115	[53–55]
Hippuric acid	2	C9H9N1O3	180.06552	3.04	5174	ND	HMDB0000714	[48,51,52,54]
Histidine	2	C6H9N3O2	156.07675	0.32	342	yes	HMDB0000177	[34,49,56]
Lactic acid	-	C3H6O3	91.03897	-	ND	ND	HMDB0000190	[35,44,52]
p-cresol	-	C7H8O1	109.06479	-	ND	ND	HMDB0001858	[34,35,53,56]
Phenylalanine	1	C9H11NO2	166.08625	1.70	594+5370+287	yes	HMDB0000159	[34,56,57]
Serine	2	C3H7NO3	106.04987	0.40	437	ND	HMDB0000187	[34,40,42,43,49]
Succinic acid	-	C4H6O4	119.03388	-	ND	ND	HMDB0000254	[40,47,48,54]
Taurine	3	C2H7NO3S	126.02194	0.43	428	ND	HMDB0000251	[25,44,47–49,52]
Threonine	2	C4H9NO3	120.06552	0.40	476	ND	HMDB0000167	[38,42,49,50]
Tryptophan	2	C11H12N2O2	205.09715	2.53	164	yes	HMDB0000929	[38,41,52,55,56]
Tyrosine	1	C9H11NO3	182.08117	0.72	58	yes	HMDB0000158	[35,42,57]
Valine	2	C5H11NO2	118.08625	0.42	ND	yes	HMDB0000883	[34,39,52]

869 ND: not detected

- 870 ¹ Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].
- 871 When the [M+H]⁺ adduct could not be found (+/- 5 ppm), common adducts were searched including [M+Na]⁺, [M+K]⁺, [M+2H]²⁺,
- 872 [M+H-H₂O]⁺.
- 873 See full list of compounds considered and more details in Additional file 11.

874 **Figures**


875 Figure 1. Feature-based molecular network displaying the 15 predominant putative chemical classes
876 and their subclasses

877 Nodes represent mass spectral features and are used as a proxy for a metabolite. Connected nodes
878 represent high tandem mass spectral similarity, and thus high chemical structural similarity. The
879 thickness of the grey edges connecting nodes varies according to the cosine score representing to what
880 extent two connected metabolites are chemically similar (based on MS2 spectra, from 0.7: less similar
881 and thin edge to 1.0: identical and thick edge).


882 The name of annotated metabolites (levels 1 and 2), details on chemical classes with fewer than 4
883 metabolites (absent on this figure), chemical classification scores [73], all unknowns, and group
884 intensities for all features (average, standard deviations) are detailed in Additional file 7.

885 [See Figure_1.pdf](#)

886



887 Figure 2. Network of molecular features putatively annotated as bile acids with average group
888 intensities, fold change values, mass differences and cosine scores displayed.
889 Molecular family #75 is composed of eight bile acid structural analogues (see details in Additional File
890 7). Coloring according to the fold change values makes it easier to spot the families with differential
891 abundance in cases vs. controls. Displaying average intensities for the three groups (cases, controls,
892 paper blanks) allows for a quick control of the noise (paper blanks, here no noise detected) and
893 confirmation of fold change. On edges, while the thickness of the connection represents to what extent
894 two metabolites are chemically similar, the mass difference is essential to support annotation as it
895 translates into how molecules differ from one another (e.g. water loss, conjugation, adducts, etc.).
896 [See Figure_2.pdf](#)
897



898 Figure 3. Bray-Curtis principal coordinates analysis of the 68 samples after outlier removal.
899 Each sphere represents one sample. Axes are principal components 1 (x) and 3 (y) explaining 18.48%
900 and 8.79% of the variability in the data, respectively. The four replicated pool injections cluster
901 satisfactorily.

902 a) Coloring reflects the type of samples, i.e. cases, controls and four replicated pool injections. No clear
903 distinction between cases and controls can be observed (PERMANOVA Adonis $R^2 = 0.014$, P-value =
904 0.777).


905 b) Coloring reflects the month of birth for the 68 samples as well as the four replicated pool injections.
906 Samples collected in the winter (dark purple and yellow, extremities of the colors scale) are positioned
907 away from the samples collected in summer (green and turquoise, middle of the color scale). 26.2% of
908 the variation in the data can be explained by month of birth (Adonis $R^2 = 0.262$, P-value = 0.001)
909 See Additional file 8 for detailed values with and without FDR correction and for other distance
910 matrices.

911 [See Figure_3ab.pdf](#)


912

a


Axis 3 (8.792 %)

**b**

Axis 3 (8.792 %)



913 Figure 4. PERMANOVAs of the four tested distance matrices showing how much of the variation
914 (Adonis R^2) is explained by a metadata variable.
915 P-values include FDR correction. A star is present when the corrected p-values was <0.05 .
916 All exact values are available in Additional file 8 and detailed metadata (subject characteristics) are
917 available in Table 1 and Additional file 6.
918 [See Figure_4.pdf](#)
919
920



921 **Additional files**

922 Additional file 1:

923 Standardized reporting of untargeted metabolomics LC-MS/MS method according to [60] containing
924 the list of internal standards from the Neobase Non-derivatized MSMS kit and their concentration in
925 the extraction buffer

926 [See .xlsx](#)

927

928 Additional file 2:

929 MZmine batch .xml file used to preprocess the raw data

930 [See .xml](#)

931

932 Additional file 3:

933 Compound Discoverer 2.1 preprocessing workflow settings

934 [See .pdf](#)

935

936 Additional file 4ab:

937 PEG (4a) and PPG (4b) filtering scripts using the Kendrick Mass filter according to [80]

938 [See the two .ipynb](#)

939 [Can be opened using https://jupyter.org/](https://jupyter.org/)

940

941 Additional file 5:

942 Targeted analysis of outliers using TraceFinder (IS and unlabeled homologs) and heatmap of
943 untargeted analysis

944 [See .pdf](#)

945

946 Additional file 6:

947 Subjects characteristics in details

948 [See .xlsx](#)

949

950 Additional file 7:

951 All features including annotated compounds. Out of the 4360 features detected, 150 could be annotated
952 by GNPS library matching (annotation level 2) or in-house Trace Finder library (annotation level 1)
953 and an additional 859 by MolNetEnhancer (annotation level 3).

954 [See .xlsx](#)

955

956 Additional file 8:

957 PERMANOVAs Adonis R^2 values and p-values calculated with (74 samples) and without (68 samples)
958 outliers

959 [See .xlsx](#)

960

961 Additional file 9:

962 Full list of compounds with t-test p value <0.01 without FDR correction and/or with Wilcoxon rank-
963 sum test p value <0.01 without FDR correction and/or case/control fold change value <0.5 or >2 .

964 [See .xlsx](#)

965

966 Additional file 10: Fragmentation profiles of the two unknown features to be monitored in future
967 studies as well as methacholine as shown in Table 2.

968 [See .pdf](#)

969

970 Additional file 11: Full list of compounds reported in the literature as involved in ASD and considered
971 in this study.

972 [See .xlsx](#)

973